日本首款恶液质新药Adlumiz上市，癌症恶病质的救星

Anamorelin () is a synthetic mimic of the N-terminal active core of ghrelin. It was developed by Novo Nordisk in 1999 and subsequently licensed by Ono and Helsinn. It is used to treat cachexia and anorexia in cancer patients. It is currently the only drug proven to alleviate the progression of cancer cachexia in multiple phase III clinical trials. Its mechanism of action is the same as that of ghrelin, which promotes the secretion of growth hormone through the activation of GHSR, thereby improving appetite and increasing body weight. It can also improve nausea and loss of appetite caused by platinum-based chemotherapy by stabilizing intracellular calcium ion homeostasis.

At present, a series of phase II and III clinical trials of the GHSR agonist Adlumiz conducted abroad have shown us that it has certain efficacy in improving patients' LBM, appetite, QoL and muscle strength, and the adverse reactions are tolerable. In 2017, a phase I clinical trial of Adlumiz was also carried out in China.

: Decreased blood pressure, worsening of diabetes, suppression of stimulation conduction system, abnormal electrocardiogram (obvious PR interval or QRS width prolongation, QT prolongation), atrioventricular block, upper ventricular extrasystoles, hyperglycemia, tachycardia, bradycardia, palpitations, increased glycosylated hemoglobin, frequent urination, increased serum γ-glutamyl transpeptidase, liver dysfunction, liver dysfunction caused by increased blood bilirubin, etc. When patients use Adlumiz, they must strictly follow the doctor's instructions and take the medication correctly, so that they can maximize the effect of Adlumiz. During the medication period, patients must not increase or decrease the dose of the drug by themselves. Adlumiz will not improve the therapeutic effect just because the dose of the drug is increased, so do not use the drug blindly.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.